TY -的T1下严重的多发性硬化复发fingolimod疗法:事件还是巧合?摩根富林明首页-神经学乔-神经病学SP - 928 LP - 930 - 10.1212 / WNL。0 b013e31824c46ad六世- 78 - 12非盟- f . Castrop盟贝拉Kowarik AU - h·阿尔布雷特盟- m . Krause AU - b Haslinger AU - c·齐默AU - a . Berthele盟- b .缝边器Y1 - 2012/03/20 UR - //www.ez-admanager.com/content/78/12/928.首页abstract N2 - Fingolimod是第一个口头管理疾病修饰药物已被批准用于治疗复发缓和多发性硬化症(MS)。磷酸化后它作为一个非选择性的功能拮抗剂sphingosine-1-phosphate受体家族(S1P1/3/4/5),捕获B和T淋巴细胞在二级淋巴组织。病例报告。一名26岁的女性被诊断为复发缓和女士在2009年2月的一集后轻微感觉赤字。她用干扰素治疗β-1a停止在2010年1月由于肝酶升高,而转向干扰素β-1b 2个月后。尽管7 steroid-responsive复发她扩大残疾状态量表(eds)保持稳定(1.0 - 1.5),直到2010年4月结束(图A和B),当她第一次温和复发2.5 (eds)。假设缺乏治疗的疗效,病人停止干扰素治疗但拒绝治疗natalizumab出于安全考虑。最终她在参加一个开放性fingolimod试验6月19日,2010年。 Figure Disease course, imaging, and laboratory results (A) The patient's disease course: bottom: results of blood immunophenotyping. (B) On May 3, 2010, 6 weeks before initiation of fingolimod therapy, the cerebral MRI (axial T2 and T1+Gd) disclosed several supratentorial and infratentorial multiple sclerosis lesions without gadolinium enhancement. The MRI was obtained immediately after a high-dose IV steroid treatment. (C) MRI at admission in September 2010. Left: the cerebral MRI (axial T2 and T1+Gd) disclosed 29 supratentorial and infratentorial ovoid as well as confluent active lesions, some with ring-like gadolinium enhancement. Moreover, there was a large lesion in the left cerebellar peduncle, without diffusion restriction in diffusion-weighted imaging (not shown). Right: MRI of the cervical and thoracic spinal … ER -